Medicared For All Logo

Allen Yeilding MD in Rockford, Alabama

Home Alabama Rockford

Allen Yeilding MD has Hematology/oncology as his primary medical specialty. Their primary office is: 9518 Us Hwy 231 in Rockford, Alabama. There are 2 additional office locations for Allen Yeilding MD that can be viewed towards the end of their profile.

They're a part of the: The Sylacauga Health Care Authority medical group which has around 30 members. You can call their office at 256-377-4366 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended University Of Alabama School Of Medicine and graduated in 1982 (around 42 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.


Allen L Yeilding MD Office Phone and Directions

Allen Yeilding MD
The Sylacauga Health Care Authority
9518 Us Hwy 231
Rockford, Alabama 35136
256-377-4366


Patient Ratings
Please rate your experience with Allen Yeilding MD below to help others make a more informed decision. Thanks!
Current Rating: Loading...

Phone: 256-377-4366


Enter a starting address:


Healthcare Info for Allen Yeilding MD

Medical School: University Of Alabama School Of Medicine
Graduation Year: 1982
The Primary Medical Specialty for Allen Yeilding MD is listed as: Hematology/oncology
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 42
PAC (PECOS ID)#: 5092614784
NPI #: 1164443792
NPI Created On: 07/21/2006
NPI Last Updated Listed as: 09/24/2013
Primary Taxonomy Code: 207RH0003X
License Number:
00010908
Listed Gender: Male

Insurance, Services, Charges


Forms of insurance accepted by include, but are not limited to:

  • Humana
  • Bright Health Insurance Company
  • Blue Cross Blue Shield
  • Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.


Services and Procedures include:

  1. Insertion of needle into vein for collection of blood sample
  2. Complete blood cell count (red cells, white blood cell, platelets), automated test
  3. Vaccine for influenza for injection into muscle
  4. Hydration infusion into a vein 31 minutes to 1 hour
  5. Hydration infusion into a vein
  6. Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour
  7. Infusion into a vein for therapy, prevention, or diagnosis
  8. Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour
  9. Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
  10. Injection of different drug or substance into a vein for therapy, diagnosis, or prevention
  11. Infusion of chemotherapy into a vein up to 1 hour
  12. Infusion of chemotherapy into a vein
  13. New patient office or other outpatient visit, typically 60 minutes
  14. Established patient office or other outpatient visit, typically 15 minutes
  15. Established patient office or other outpatient visit, typically 15 minutes
  16. Established patient office or other outpatient, visit typically 25 minutes
  17. Established patient office or other outpatient, visit typically 25 minutes
  18. Initial hospital inpatient care, typically 70 minutes per day
  19. Subsequent hospital inpatient care, typically 25 minutes per day
  20. Subsequent hospital inpatient care, typically 35 minutes per day

They took part in Medicare's Electronic Health Record Incentive Program which was designed to help move people over to electronic records and improve the systems that were already in place.
They took part in the Medicare Physician Quality Reporting System (PQRS).

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.


Payments Total: $13

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941783

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: IMBRUVICA

Open Associated Drug #1: 57962-140-09

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: DARZALEX

Associated Drug #2: 57894-502-05


Payments Total: $22

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941777

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: ERLEADA

Open Associated Drug #1: 59676-600-12

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: BALVERSA

Associated Drug #2: 59676-030-56


Payments Total: $18

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941779

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $5

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941781

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $16

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941785

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $15

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941787

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: IMBRUVICA

Open Associated Drug #1: 57962-140-09

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: DARZALEX

Associated Drug #2: 57894-502-05


Payments Total: $15

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941789

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: IMBRUVICA

Open Associated Drug #1: 57962-140-09

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: DARZALEX

Associated Drug #2: 57894-502-05


Payments Total: $11

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941791

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $16

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941793

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $17

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 787941795

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: IMBRUVICA

Open Associated Drug #1: 57962-140-09

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: DARZALEX

Associated Drug #2: 57894-502-05


Additional Office Locations

1. The Sylacauga Health Care Authority
315 W Hickory St
Sylacauga, AL 35150
Group Members: 30

Phone: 256-377-4366

Enter a starting address:


2. Hematology And Oncology Associates Of Alabama, Llc
513 Brookwood Blvd
Birmingham, AL 35209
Suite 275
Group Members: 8

Phone: 256-377-4366

Enter a starting address:


Hematology/oncology Professionals in Rockford

9518 Us Hwy 231
Rockford, AL
The Sylacauga Health Care Authority

9518 Us Hwy 231
Rockford, AL
The Sylacauga Health Care Authority

9518 Us Hwy 231
Rockford, AL
The Sylacauga Health Care Authority

Providers in The Sylacauga Health Care Authority

1.Mohamed Aldaher

315 W Hickory St
Sylacauga Al 35150-2913
The Sylacauga Health Care Authority
Internal Medicine

2.Khaleel Ashraf Md

9518 Us Hwy 231
Rockford Al 35136-5214
The Sylacauga Health Care Authority
Hematology/oncology

3.Khaleel Ashraf Md

315 W Hickory St
Sylacauga Al 35150-2913
The Sylacauga Health Care Authority
Hematology/oncology

4.Kevin Bevis

315 W Hickory St
Sylacauga Al 35150-2913
The Sylacauga Health Care Authority
Anesthesiology

5.Tasia Bradford

209 W Spring St
Sylacauga Al 35150-2974
The Sylacauga Health Care Authority
Nurse Practitioner

6.Jonathan Bridges

9518 Us Hwy 231
Rockford Al 35136-5214
The Sylacauga Health Care Authority
Hematology/oncology

View all 30 members of The Sylacauga Health Care Authority medical group